Latest Cytokinetics Inc (CYTK) Headlines Cytoki
Post# of 67
Posted On: 03/12/2014 8:05:22 PM
Latest Cytokinetics Inc (CYTK) Headlines
Cytokinetics Up 17.6% Since SmarTrend Uptrend Call (CYTK)
Comtex SmarTrend(R) - Wed Mar 12, 9:56AM CDT
SmarTrend identified an Uptrend for Cytokinetics (NASDAQ:CYTK) on February 10th, 2014 at $8.74. In approximately 1 month, Cytokinetics has returned 17.62% as of today's recent price of $10.28.
Cytokinetics Shares Up 24.0% Since SmarTrend's Buy Recommendation (CYTK)
Comtex SmarTrend(R) - Wed Mar 05, 9:27AM CST
SmarTrend identified an Uptrend for Cytokinetics (NASDAQ:CYTK) on February 10th, 2014 at $8.74. In approximately 3 weeks, Cytokinetics has returned 24.03% as of today's recent price of $10.84.
Stock Movements, Upcoming Conferences, Financial Results, and Public Offering Closings - Analyst Notes on Community Health Systems, United Therapeutics, Thoratec, AMRI, and Cytokinetics
PR Newswire - Wed Mar 05, 6:15AM CST
Editor Note: For more information about this release, please scroll to bottom.
Cytokinetics to Present at Upcoming Healthcare Conferences
Thomson Reuters ONE - Fri Feb 28, 3:01PM CST
South San Francisco, CA, February 28, 2014 - Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that members of its management team are scheduled to participate at the following healthcare conferences:
Multiple Insiders of Cytokinetics, Incorporated (CYTK)-NasdaqCM bought Shares of CYTK
M2 - Fri Feb 28, 8:34AM CST
Reported by InsiderCow.com at 2014-02-27 15:33:52 ET
Shares of CYTK Up 15.1% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Wed Feb 26, 9:28AM CST
SmarTrend identified an Uptrend for Cytokinetics (NASDAQ:CYTK) on February 10th, 2014 at $8.74. In approximately 2 weeks, Cytokinetics has returned 15.10% as of today's recent price of $10.06.
Cytokinetics Announces Closing of its Public Offering of Common Stock and Exercise of Option to Purchase Additional Shares
Thomson Reuters ONE - Tue Feb 25, 3:00PM CST
Trade-Ideas: Cytokinetics (CYTK) Is Today's "Dead Cat Bounce" Stock
at The Street - Fri Feb 21, 8:59AM CST
Trade-Ideas LLC identified Cytokinetics (CYTK) as a "dead cat bounce" (down big yesterday but up big today) candidate
Cytokinetics Announces pricing of $35.0 Million Public Offering of Common Stock
Thomson Reuters ONE - Thu Feb 20, 7:56AM CST
South San Francisco, CA, February 20, 2014 - Cytokinetics, Incorporated (Nasdaq: CYTK) announced today the pricing of its previously announced underwritten public offering of 4,375,000 shares of its common stock at a price to the public of $8.00 per share. Cytokinetics anticipates its aggregate gross proceeds will be approximately $35.0 million before deducting the underwriting discount and estimated offering expenses payable by Cytokinetics. In addition, Cytokinetics has granted the underwriters a 30 day option to purchase up to an additional 656,250 shares of common stock under the same terms and conditions solely to cover over-allotments, if any. All of the shares in the offering are to be sold by Cytokinetics. The offering is expected to close on or about February 25, 2014, subject to the satisfaction of customary closing conditions.
Cytokinetics Announces Proposed Public Offering of Common Stock
Thomson Reuters ONE - Wed Feb 19, 3:01PM CST
South San Francisco, CA, February 19, 2014 - Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that it intends to offer and sell shares of its common stock in an underwritten public offering. Cytokinetics also expects to grant the underwriters an option to purchase up to an additional 15% of the shares of common stock offered in the public offering, exercisable for 30 days. All of the shares in the proposed offering are to be sold by Cytokinetics. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Biotech Stock Roundup: Gilead's Sovaldi Impresses, EU Nod for Biogen's Tecfidera - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Feb 12, 7:27AM CST
Last week saw companies like Gilead coming out with strong results. There were also a few regulatory updates.
Cytokinetics Rises on Q4 Earnings Beat - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 10, 10:00AM CST
Cytokinetics reported fourth quarter 2013 earnings of 21 cents.
Cytokinetics, Incorporated (CYTK) Soars: Stock Up 26% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Feb 10, 7:51AM CST
Cytokinetics, Incorporated was a big mover last session, as its shares surged over 26% on the day.
Form 4: Update Filing for Crawford & Co (CRD/A)
Vickers Stock Research - Sat Feb 08, 4:47AM CST
South San Francisco, CA., February 8, 2013 - Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that Robert I. Blum, President and Chief Executive Officer, is scheduled to present a corporate update at the BIO CEO and Investor Conference on Monday, February 11, 2013 at 1:30 p.m. Eastern Standard Time in the East Foyer Room of the Waldorf Astoria Hotel in New York, New York.
Form 4: Update Filing for Astoria Financial Corp (AF)
Vickers Stock Research - Sat Feb 08, 4:25AM CST
Steve Dow Will Not Stand for Re-Election at the Annual Meeting of Shareholders;
3 Stocks That Absolutely Crushed the Market on Friday -- Here's Why athenahealth inc, Puma Biotechno
David Williamson, The Motley Fool - Motley Fool - Fri Feb 07, 6:05PM CST
Several companies benefited from an overall biotech bounce-back today, but Athenahealth , Puma Biotechnology and Cytokinetics were three health-care stocks that saw big pops on specific company news, which made them today's winners in the...
Nasdaq stocks posting largest percentage increases
AP - Fri Feb 07, 12:40PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
Why Cytokinetics Inc. Shares Soared
Sean Williams, The Motley Fool - Motley Fool - Fri Feb 07, 12:39PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Cytokinetics , a clinical-stage...
Cytokinetics, Incorporated Reports Fourth Quarter 2013 Financial Results
Thomson Reuters ONE - Thu Feb 06, 3:00PM CST
Company Summarizes Recent Progress in Development Programs and Provides Expected Milestones and Financial Guidance for 2014
Cytokinetics Up 17.6% Since SmarTrend Uptrend Call (CYTK)
Comtex SmarTrend(R) - Wed Mar 12, 9:56AM CDT
SmarTrend identified an Uptrend for Cytokinetics (NASDAQ:CYTK) on February 10th, 2014 at $8.74. In approximately 1 month, Cytokinetics has returned 17.62% as of today's recent price of $10.28.
Cytokinetics Shares Up 24.0% Since SmarTrend's Buy Recommendation (CYTK)
Comtex SmarTrend(R) - Wed Mar 05, 9:27AM CST
SmarTrend identified an Uptrend for Cytokinetics (NASDAQ:CYTK) on February 10th, 2014 at $8.74. In approximately 3 weeks, Cytokinetics has returned 24.03% as of today's recent price of $10.84.
Stock Movements, Upcoming Conferences, Financial Results, and Public Offering Closings - Analyst Notes on Community Health Systems, United Therapeutics, Thoratec, AMRI, and Cytokinetics
PR Newswire - Wed Mar 05, 6:15AM CST
Editor Note: For more information about this release, please scroll to bottom.
Cytokinetics to Present at Upcoming Healthcare Conferences
Thomson Reuters ONE - Fri Feb 28, 3:01PM CST
South San Francisco, CA, February 28, 2014 - Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that members of its management team are scheduled to participate at the following healthcare conferences:
Multiple Insiders of Cytokinetics, Incorporated (CYTK)-NasdaqCM bought Shares of CYTK
M2 - Fri Feb 28, 8:34AM CST
Reported by InsiderCow.com at 2014-02-27 15:33:52 ET
Shares of CYTK Up 15.1% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Wed Feb 26, 9:28AM CST
SmarTrend identified an Uptrend for Cytokinetics (NASDAQ:CYTK) on February 10th, 2014 at $8.74. In approximately 2 weeks, Cytokinetics has returned 15.10% as of today's recent price of $10.06.
Cytokinetics Announces Closing of its Public Offering of Common Stock and Exercise of Option to Purchase Additional Shares
Thomson Reuters ONE - Tue Feb 25, 3:00PM CST
Trade-Ideas: Cytokinetics (CYTK) Is Today's "Dead Cat Bounce" Stock
at The Street - Fri Feb 21, 8:59AM CST
Trade-Ideas LLC identified Cytokinetics (CYTK) as a "dead cat bounce" (down big yesterday but up big today) candidate
Cytokinetics Announces pricing of $35.0 Million Public Offering of Common Stock
Thomson Reuters ONE - Thu Feb 20, 7:56AM CST
South San Francisco, CA, February 20, 2014 - Cytokinetics, Incorporated (Nasdaq: CYTK) announced today the pricing of its previously announced underwritten public offering of 4,375,000 shares of its common stock at a price to the public of $8.00 per share. Cytokinetics anticipates its aggregate gross proceeds will be approximately $35.0 million before deducting the underwriting discount and estimated offering expenses payable by Cytokinetics. In addition, Cytokinetics has granted the underwriters a 30 day option to purchase up to an additional 656,250 shares of common stock under the same terms and conditions solely to cover over-allotments, if any. All of the shares in the offering are to be sold by Cytokinetics. The offering is expected to close on or about February 25, 2014, subject to the satisfaction of customary closing conditions.
Cytokinetics Announces Proposed Public Offering of Common Stock
Thomson Reuters ONE - Wed Feb 19, 3:01PM CST
South San Francisco, CA, February 19, 2014 - Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that it intends to offer and sell shares of its common stock in an underwritten public offering. Cytokinetics also expects to grant the underwriters an option to purchase up to an additional 15% of the shares of common stock offered in the public offering, exercisable for 30 days. All of the shares in the proposed offering are to be sold by Cytokinetics. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Biotech Stock Roundup: Gilead's Sovaldi Impresses, EU Nod for Biogen's Tecfidera - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Feb 12, 7:27AM CST
Last week saw companies like Gilead coming out with strong results. There were also a few regulatory updates.
Cytokinetics Rises on Q4 Earnings Beat - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 10, 10:00AM CST
Cytokinetics reported fourth quarter 2013 earnings of 21 cents.
Cytokinetics, Incorporated (CYTK) Soars: Stock Up 26% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Feb 10, 7:51AM CST
Cytokinetics, Incorporated was a big mover last session, as its shares surged over 26% on the day.
Form 4: Update Filing for Crawford & Co (CRD/A)
Vickers Stock Research - Sat Feb 08, 4:47AM CST
South San Francisco, CA., February 8, 2013 - Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that Robert I. Blum, President and Chief Executive Officer, is scheduled to present a corporate update at the BIO CEO and Investor Conference on Monday, February 11, 2013 at 1:30 p.m. Eastern Standard Time in the East Foyer Room of the Waldorf Astoria Hotel in New York, New York.
Form 4: Update Filing for Astoria Financial Corp (AF)
Vickers Stock Research - Sat Feb 08, 4:25AM CST
Steve Dow Will Not Stand for Re-Election at the Annual Meeting of Shareholders;
3 Stocks That Absolutely Crushed the Market on Friday -- Here's Why athenahealth inc, Puma Biotechno
David Williamson, The Motley Fool - Motley Fool - Fri Feb 07, 6:05PM CST
Several companies benefited from an overall biotech bounce-back today, but Athenahealth , Puma Biotechnology and Cytokinetics were three health-care stocks that saw big pops on specific company news, which made them today's winners in the...
Nasdaq stocks posting largest percentage increases
AP - Fri Feb 07, 12:40PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
Why Cytokinetics Inc. Shares Soared
Sean Williams, The Motley Fool - Motley Fool - Fri Feb 07, 12:39PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Cytokinetics , a clinical-stage...
Cytokinetics, Incorporated Reports Fourth Quarter 2013 Financial Results
Thomson Reuters ONE - Thu Feb 06, 3:00PM CST
Company Summarizes Recent Progress in Development Programs and Provides Expected Milestones and Financial Guidance for 2014
(0)
(0)